home
about us
member log-in
contact us

PRODUCTS
MUNICIPAL BONDS
INDEX FUNDS
- Total Asset Fund (TAF)
EVENTS
MARKET RESEARCH

Recent Quotes

View Full List

My Watchlist

Indicators

Markets:

Overview

News

Currencies

International

Treasuries

Regeneron Pharmaceuticals (NQ:REGN)

638.88 -3.71 (-0.58%)

Streaming Delayed Price Updated: 4:00 PM EDT, May 22, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Regeneron Pharmaceuticals

< Previous 1 2

...

15 16 17 18 19 20 21 22 23

...

62 63 Next >

Why Regeneron Pharmaceuticals Stock Topped the Market on Tuesday ↗

February 04, 2025

Via The Motley Fool

Uncover the latest developments among S&P500 stocks in today's session. ↗

February 04, 2025

Let's have a look at what is happening on the US markets one hour before the close of the markets on Tuesday. Below you can find the top S&P500 gainers and losers in today's session.

Via Chartmill

Discover which S&P500 stocks are making waves on Tuesday. ↗

February 04, 2025

Get insights into the S&P500 index performance on Tuesday. Explore the top gainers and losers within the S&P500 index in today's session.

Via Chartmill

Regeneron Pharma Q4 Earnings Crush Estimates, Initiates Dividend And Additional Stock Buyback Program ↗

February 04, 2025

Regeneron beat Q4 estimates with $12.07 EPS and $3.79B in sales. The company announced a dividend, a $3 billion buyback, and continued R&D investments.

Via Benzinga

Beyond The Numbers: 18 Analysts Discuss Regeneron Pharmaceuticals Stock ↗

January 28, 2025

Via Benzinga

Looking Into Regeneron Pharmaceuticals's Recent Short Interest ↗

January 24, 2025

Via Benzinga

$100 Invested In This Stock 15 Years Ago Would Be Worth This Much Today ↗

January 16, 2025

Via Benzinga

US Stocks Rise Despite China's Trade Fears, Palantir Defies Gravity, Gold Rallies Further: What's Driving Markets Tuesday? ↗

February 04, 2025

U.S. stocks advanced midday Tuesday, demonstrating resilience despite escalating geopolitical tensions and trade uncertainties between the world’s two largest economies.

Via Benzinga

INVESTOR ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Regeneron Pharmaceuticals

February 04, 2025

From Faruqi & Faruqi LLP

Via GlobeNewswire

Regeneron Advances On Fourth-Quarter Beat As Eylea Meets Expectations ↗

February 04, 2025

Regeneron stock rose early Tuesday on a strong fourth-quarter report that included in-line sales of eye drug Eylea.

Via Investor's Business Daily

Regeneron’s (NASDAQ:REGN) Q4 Sales Top Estimates, Stock Soars

February 04, 2025

Biotech company Regeneron (NASDAQ:REGN) reported Q4 CY2024 results topping the market’s revenue expectations, with sales up 10.3% year on year to $3.79 billion. Its non-GAAP profit of $12.07 per share...

Via StockStory

Regeneron Reports Fourth Quarter and Full Year 2024 Financial and Operating Results; Initiates Quarterly Dividend and Increases Total Share Repurchase Capacity to ~$4.5 Billion

February 04, 2025

From Regeneron Pharmaceuticals, Inc.

Via GlobeNewswire

Earnings Scheduled For February 4, 2025 ↗

February 04, 2025

Via Benzinga

DEADLINE REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Regeneron Pharmaceuticals

January 29, 2025

From Faruqi & Faruqi LLP

Via GlobeNewswire

REGENERON ALERT: Bragar Eagel & Squire, P.C. is Investigating Regeneron Pharmaceuticals, Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm

January 28, 2025

From Bragar Eagel & Squire

Via GlobeNewswire

9 Health Care Stocks With Whale Alerts In Today's Session ↗

January 28, 2025

Via Benzinga

America’s Top 40 High School Scientists to Compete for $1.8 Million in Awards at Prestigious Regeneron Science Talent Search

January 23, 2025

The Regeneron Science Talent Search Celebrates and Rewards Today’s Most Talented Young Minds Driving Innovation and Progress through Scientific Exploration

From Regeneron Pharmaceuticals, Inc.

Via GlobeNewswire

DEADLINE ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Regeneron Pharmaceuticals

January 22, 2025

From Faruqi & Faruqi LLP

Via GlobeNewswire

REGN INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Regeneron Pharmaceuticals, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit

January 21, 2025

From Bronstein, Gewirtz & Grossman, LLC

Via Business Wire

INVESTOR REMINDER: Berger Montague Notifies Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) Investors of a Class Action Lawsuit and Deadline

January 21, 2025

From Berger Montague

Via GlobeNewswire

ROSEN, A RANKED AND LEADING FIRM, Encourages Regeneron Pharmaceuticals, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – REGN

January 19, 2025

From The Rosen Law Firm PA

Via GlobeNewswire

Robbins LLP Urges REGN Stockholders with Large Losses to Contact the Firm for Information About the Class Action Against Regeneron Pharmaceuticals, Inc

January 17, 2025

From Robbins LLP

Via GlobeNewswire

Stock Market Rises On Tame Inflation, Bank Earnings: Weekly Review ↗

January 17, 2025

Many stocks flashed buy signals as the major indexes rose to or above key levels.

Via Investor's Business Daily

Topics Economy

NASDAQ: REGN INVESTOR ALERT: Berger Montague Advises Regeneron Pharmaceuticals (NASDAQ: REGN) Investors of a March 10, 2025 Deadline

January 17, 2025

From Berger Montague

Via GlobeNewswire

Why Verona Pharma, A Triple-Digit Gainer In 2024, Surged Another 22% This Week ↗

January 16, 2025

The company is working to launch its COPD treatment more broadly. The drug is a non-steroidal nebulizer.

Via Investor's Business Daily

Rosen Law Firm Urges Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) Stockholders to Contact the Firm for Information About Their Rights

January 14, 2025

From The Rosen Law Firm, P.A.

Via Business Wire

Deadline Approaching: Regeneron Pharmaceuticals, Inc. (REGN) Investors Who Lost Money Urged to Contact Law Offices of Howard G. Smith

January 14, 2025

From Law Offices of Howard G. Smith

Via Business Wire

Regeneron Pipeline Aims To Address $220 Billion Therapeutic Opportunities By 2030 ↗

January 14, 2025

Regeneron promotes EYLEA, Libtayo, and Dupixent at JPMorgan event while touting a pipeline that targets major disease areas.

Via Benzinga

REGN Shareholder Alert: Shareholder Rights Law Firm Robbins LLP Reminds Investors Class Action Against Regeneron Pharmaceuticals, Inc.

January 13, 2025

From Robbins LLP

Via GlobeNewswire

REGN INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Regeneron Pharmaceuticals, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit

January 13, 2025

From Bronstein, Gewirtz & Grossman, LLC

Via Business Wire

< Previous 1 2

...

15 16 17 18 19 20 21 22 23

...

62 63 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.

Home
About Us
Products
Municipal Bonds
Index Funds
Seminars & Events
Market Research
Contact Us
Member Section
Privacy Policy
Terms & Conditions
Security Notice
Customer Service

Securities offered through Purshe Kaplan Sterling Investments, member FINRA / SIPC, Headquartered at 80 State Street,
Albany, NY 12207
Purshe Kaplan Sterling Investments and Tamar Securities, LLC are not affiliated companies.
Tamar Securities, LLC is a Registered Investment Adviser. Advisory services are only offered to clients or prospective clients where Tamar Securities, LLC
and its representatives are properly licensed or exempt from licensure. Past performance is no guarantee of future returns. Investing involves risk and possible loss of principal capital.
No advice may be rendered by Tamar Securities, LLC unless a client service agreement is in place.

NOT FDIC INSURED. NOT BANK GUARANTEED. MAY LOSE VALUE, INCLUDING LOSS OF PRINCIPAL. NOT INSURED BY ANY STATE OR FEDERAL AGENCY.
Web development by IBCnet.com